# Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

> **NCT04423861** · PHASE3 · UNKNOWN · sponsor: **Azidus Brasil** · enrollment: 380 (estimated)

## Conditions studied

- covid19

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04423861
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-22
- **Primary completion:** 2023-03
- **Final completion:** 2023-03
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423861, "Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04423861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*